两种免疫调节剂辅助LAK细胞杀伤喉癌细胞的体外研究

为探讨如何提高白细胞介素－２（ＩＬ－２）／ＬＡＫ细胞过继免疫治疗的抗肿瘤作用，应用免疫调节剂分枝杆菌多糖或ＣＤ３单克隆抗体协同ＩＬ－２诱导的健康人外周血淋巴细胞来源的ＬＡＫ细胞在体外扩增，测定其对喉癌ＨＥＰ－２细胞杀伤活性。实验结果：（１）不同免疫调节剂对ＬＡＫ细胞扩增的影响。实验组三且细胞于体外扩增均明显高于对照组（Ｐ〈０．０１）；ＭＰＳ组或ＣＤ３组细胞的扩增倍数比单纯应用ＩＬ－２组为高（Ｐ〈０

The study of effects of immunologic modifier on proliferation and cytotoxicity against HEP-2 of LAK cells in vitro]

Adoptive immunotherapy as a new approach has been used to treat advanced carcinoma for almost ten years, and gained some good results. However, the application of this method is largely restricted by the side effects along with high dose of IL-2 and lack of sufficient amount of LAK cells. Mycobacterial Polysaccharides (MPS) and anti-CD3 antibodies (CD3Ab) have been demonstrated to be effective immunologic modifiers capable of proliferating lymphocytes and increasing cytotoxity against tumor cells. In this article we discussed the effects of MPS and CD3Ab on proliferation and cytotoxity against HEP-2 cells of LAK cells. Our results showed that: 1. MPS group (incubating IL-2 2 x 10(5)/L plus MPS 0.4 mg/L) or CD3 group (IL-2 1 x 10(6)/L plus CD3Ab 4 mg/L) were more proliferative than LAK group (only incubated with IL-2 1 x 10(6)/L). MPS group is the most proliferative in the three groups, P < 0.05. 2. Cytotoxity against HEP-2 in MPS or CD3 group was also better than in LAK group. CD3 group could maintain good cytotoxity in the longest period. These results could provide guidance for adoptive immunotherapy assisted by MPS or CD3Ab.